Source link : https://www.newshealth.biz/health-news/daratumumab-plus-lenalidomide-improves-mrd-outcomes/
RIO DE JANEIRO — The addition of daratumumab to lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) significantly improves rates of achieving minimal residual disease (MRD) negativity and progression-free survival (PFS) among patients newly diagnosed with multiple myeloma (MM), new research showed. “To date, no randomized trial has directly compared daratumumab-based maintenance therapy vs […]
Author : News Health
Publish date : 2024-09-30 07:05:25
Copyright for syndicated content belongs to the linked Source.
Categories